SequelSEC

Dyne Therapeutics, Inc. DYN

Pharmaceutical Preparations · CIK 0001818794 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$468.18M
Fiscal year ended 2025-12-31
Free cash flow
-$405.13M
Fiscal year ended 2025-12-31

Dyne Therapeutics, Inc. (DYN) reported net income of -$446.21M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Dyne Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Dyne Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$468.18M-$343.89M-$242.16M-$170.96M-$150.02M-$58.65M-$13.83M
Net income-$446.21M-$317.42M-$235.94M-$168.10M-$149.29M-$59.44M-$14.86M
Research & development$398.33M$281.41M$210.76M$142.76M$121.31M$45.20M$11.04M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0UnavailableUnavailableUnavailableUnavailable
Diluted EPS$-3.47$-3.37$-3.95$-3.23$-2.93UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$69.85M$62.48M$31.40M$28.20M$28.72M$13.45M$2.79M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Dyne Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$893.37M$435.45M$121.63M$172.15M$200.82M$300.85M$14.63M
Total assets$1.19B$691.23M$165.08M$306.32M$425.66M$353.33M$16.44M
Current assets$1.13B$659.28M$129.38M$265.59M$382.39M$349.09M$14.76M
Total liabilities$214.83M$61.40M$73.79M$53.96M$57.47M$10.97M$2.40M
Current liabilities$50.62M$42.26M$51.10M$28.09M$28.72M$10.97M$2.36M
Total equity incl. NCI$972.13M$629.84M$91.29M$252.36M$368.20M$342.37M$14.04M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$148.92M$0UnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$8.08M$6.56M$22.94M$5.26M$4.03M$3.44M$1.26M

Cash flow

Dyne Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$403.21M-$292.37M-$188.16M-$153.64M-$119.56M-$46.51M-$11.83M
Capital expenditures$1.92M$2.38M$729.00K$3.07M$3.62M$1.16M$1.65M
Investing cash flow-$28.75M-$204.08M$83.31M$87.20M-$137.89M-$45.66M-$1.65M
Financing cash flow$890.31M$809.90M$54.32M$37.39M$157.82M$380.69M$19.99M
Net change in cash$458.35M$313.45M-$50.52M-$29.05M-$99.63M$288.52M$6.51M
Stock-based compensation$45.85M$45.86M$19.97M$15.18M$17.54M$6.59M$26.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$2.05M$1.67M$1.67M$1.68M$1.09M$700.00K$271.00K

Derived

Dyne Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$405.13M-$294.74M-$188.89M-$156.71M-$123.18M-$47.67M-$13.48M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio22.25x15.60x2.53x9.46x13.31x31.83x6.26x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.15xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DYN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-07-28View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.